A breast cancer drug - which keeps the disease stable for up to four times longer than the previous treatment - will be publicly funded from next month.
The phase 1/2 study will assess next-generation immunotherapy alone and in combination with an immune checkpoint inhibitor in ...
A phase 2 study for patients with HR-positive, HER2-negative metastatic breast cancer will be evaluating alisertib plus ...
Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news. If you’re covering the American Society of Hematology (ASH) Annual Meeting, Dec. 7-10 in San ...
Researchers at Baylor College of Medicine and Rice University have received a $2.3 million Breakthrough Award from the ...
Elacestrant, a selective estrogen receptor degrader, demonstrated significant improvements in progression-free survival (PFS) ...
Barbara O’Brien, MD, discusses the next steps of the phase 2 TBCRC049 study for the treatment of patients with HER2-positive ...
A new study has shed light on a previously poorly understood aspect of breast cancer recurrence: how cancer cells survive in bone marrow despite targeted therapies.
Top Forbes | SHOOK financial advisors and Wall Street investment firms have pledged more than $500,000 toward development of ...
The Data Safety Monitoring Board (DSMB) stated no safety concerns, and recommended continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ ...
SABCS ® "Spotlight” poster to be presented on Wednesday, December 11, 2024 7:00 AM - 8:30 AM CST highlights positive BriaCell survival and clinical benefit data across all metastatic breast cancer ...